News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
719,523 Results
Type
Article (42535)
Company Profile (294)
Press Release (676694)
Multimedia
Podcasts (81)
Webinars (12)
Section
Business (210474)
Career Advice (2092)
Deals (36634)
Drug Delivery (107)
Drug Development (83062)
Employer Resources (175)
FDA (16586)
Job Trends (15417)
News (356107)
Policy (33929)
Tag
Academia (2598)
Accelerated approval (5)
Adcomms (21)
Allergies (92)
Alliances (51450)
ALS (97)
Alzheimer's disease (1402)
Antibody-drug conjugate (ADC) (140)
Approvals (16582)
Artificial intelligence (277)
Autoimmune disease (24)
Automation (16)
Bankruptcy (371)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (112)
Biotechnology (188)
Bladder cancer (78)
Brain cancer (29)
Breast cancer (293)
Cancer (2346)
Cardiovascular disease (188)
Career advice (1753)
Career pathing (31)
CAR-T (155)
Cell therapy (440)
Cervical cancer (20)
Clinical research (67622)
Collaboration (877)
Company closure (2)
Compensation (564)
Complete response letters (25)
COVID-19 (2663)
CRISPR (47)
C-suite (257)
Cystic fibrosis (105)
Data (2313)
Decentralized trials (2)
Denatured (29)
Depression (47)
Diabetes (279)
Diagnostics (6463)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (115)
Drug shortages (28)
Duchenne muscular dystrophy (97)
Earnings (88687)
Editorial (41)
Employer branding (21)
Employer resources (149)
Events (115502)
Executive appointments (753)
FDA (17971)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (775)
Gene editing (116)
Generative AI (21)
Gene therapy (325)
GLP-1 (757)
Government (4550)
Grass and pollen (5)
Guidances (150)
Healthcare (19002)
Huntington's disease (25)
IgA nephropathy (28)
Immunology and inflammation (131)
Indications (30)
Infectious disease (2808)
Inflammatory bowel disease (147)
Inflation Reduction Act (8)
Influenza (52)
Intellectual property (99)
Interviews (323)
IPO (16800)
IRA (47)
Job creations (4060)
Job search strategy (1492)
Kidney cancer (10)
Labor market (43)
Layoffs (499)
Leadership (18)
Legal (8380)
Liver cancer (77)
Lung cancer (326)
Lymphoma (158)
Machine learning (9)
Management (59)
Manufacturing (338)
MASH (75)
Medical device (13468)
Medtech (13473)
Mergers & acquisitions (20398)
Metabolic disorders (726)
Multiple sclerosis (82)
NASH (17)
Neurodegenerative disease (96)
Neuropsychiatric disorders (29)
Neuroscience (1971)
NextGen: Class of 2025 (6637)
Non-profit (4528)
Now hiring (40)
Obesity (386)
Opinion (229)
Ovarian cancer (81)
Pain (103)
Pancreatic cancer (89)
Parkinson's disease (152)
Partnered (21)
Patents (247)
Patient recruitment (116)
Peanut (49)
People (59321)
Pharmaceutical (91)
Pharmacy benefit managers (20)
Phase I (20973)
Phase II (29759)
Phase III (22291)
Pipeline (1358)
Policy (159)
Postmarket research (2654)
Preclinical (8941)
Press Release (68)
Prostate cancer (108)
Psychedelics (31)
Radiopharmaceuticals (251)
Rare diseases (402)
Real estate (6258)
Recruiting (67)
Regulatory (23187)
Reports (47)
Research institute (2369)
Resumes & cover letters (358)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (78)
Series A (134)
Series B (88)
Service/supplier (12)
Sickle cell disease (55)
Special edition (17)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3729)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (52)
The Weekly (50)
Vaccines (718)
Venture capitalists (42)
Weight loss (255)
Women's health (36)
Worklife (16)
Date
Today (32)
Last 7 days (940)
Last 30 days (3049)
Last 365 days (32890)
2025 (11861)
2024 (35770)
2023 (40630)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (781)
Alabama (54)
Alaska (7)
Arizona (240)
Arkansas (14)
Asia (40762)
Australia (6527)
California (6405)
Canada (2074)
China (549)
Colorado (274)
Connecticut (279)
Delaware (159)
Europe (87090)
Florida (950)
Georgia (212)
Idaho (57)
Illinois (559)
India (26)
Indiana (327)
Iowa (11)
Japan (175)
Kansas (106)
Kentucky (24)
Louisiana (11)
Maine (62)
Maryland (927)
Massachusetts (4796)
Michigan (225)
Minnesota (403)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (67)
New Hampshire (63)
New Jersey (1800)
New Mexico (29)
New York (1806)
North Carolina (1006)
North Dakota (8)
Northern California (2812)
Ohio (208)
Oklahoma (14)
Oregon (39)
Pennsylvania (1428)
Puerto Rico (13)
Rhode Island (33)
South America (1163)
South Carolina (25)
South Dakota (1)
Southern California (2411)
Tennessee (105)
Texas (954)
United States (24106)
Utah (190)
Virginia (160)
Washington D.C. (64)
Washington State (570)
West Virginia (3)
Wisconsin (59)
719,523 Results for "oric pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
May 6, 2025
·
9 min read
Press Releases
ORIC® Pharmaceuticals to Participate in Upcoming April 2025 Investor Conferences
April 1, 2025
·
1 min read
Press Releases
ORIC® Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 25, 2025
·
5 min read
Press Releases
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 2, 2025
May 5, 2025
·
4 min read
Press Releases
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting
April 28, 2025
·
6 min read
Press Releases
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
January 27, 2025
·
1 min read
Press Releases
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 4, 2025
April 7, 2025
·
4 min read
Press Releases
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - March 7, 2025
March 10, 2025
·
4 min read
Press Releases
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
February 18, 2025
·
10 min read
Press Releases
ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones
January 13, 2025
·
10 min read
1 of 71,953
Next
